secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008070
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024
--------------------------------------------------------------------------------

- Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.
- Cash and equivalents $32.4M as of March 31, 2024, up from $21.6M at Dec 31, 2023; runway into Q3 2025.
- FDA cleared IND for APR-1051 (WEE1 inhibitor) in March 2024; Phase 1 ACESOT-1051 trial expected to start June 2024.
- Phase 1/2a ATRN-119 (ATR inhibitor) trial continues; dose escalation completion expected 4Q 2024; initial efficacy data possible 2H 2024.
- Completed $16M upfront private placement in March 2024 with potential for additional $18M warrants; appointed Nadeem Mirza as CMO effective May 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/0001558370-24-008070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/apre-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer